Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imiquimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 known ✓ | Q9NYK1 | 15/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | HRH2 | P25021 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | NUDT1 | P36639 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | TEK | Q02763 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imiquimod SCHEMBL26136 | 1.00 | TLR7 (1.00) | TLR7PDE4DADORA2ALMNAPOLB | |
| Imiquimod SCHEMBL29357252 | 1.00 | TLR7 (1.00) | TLR7PDE4DADORA2ALMNAPOLB | |
| Imiquimod SCHEMBL17962753 | 0.99 | TLR7 (0.97) | TLR7PDE4DADORA2ALMNAPOLB | |
| Imiquimod SCHEMBL1301796 | 0.99 | TLR7 (0.97) | TLR7PDE4DADORA2ALMNAPOLB | |
| Imiquimod SCHEMBL29029396 | 0.96 | TLR7 (0.93) | TLR7PDE4DADORA2ALMNAPOLB | |
| Imiquimod SCHEMBL5262205 | 0.94 | TLR7 (0.88) | TLR7PDE4DADORA2ALMNAPOLB | |
| Imiquimod SCHEMBL3191041 | 0.93 | TLR7 (0.86) | TLR7PDE4DADORA2ALMNAPOLB | |
| Imiquimod SCHEMBL3415170 | 0.92 | TLR7 (0.84) | TLR7PDE4DADORA2ALMNAPOLB | |
| Imiquimod SCHEMBL5260618 | 0.91 | TLR7 (0.82) | TLR7PDE4DADORA2ALMNAPOLB | |
| Imiquimod SCHEMBL9602834 | 0.91 | TLR7 (0.82) | TLR7PDE4DADORA2ALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11850245-B2 | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230020422-A1 | LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS | SALIX PHARMACEUTICALS, LTD. | 2023-01-19 | — | — | US | disclosed |
| US-20220160729-A1 | Replacement of Cytotoxic Preconditioning Before Cellular Immunotherapy | AVM BIOTECHNOLOGY, LLC (US) | 2022-05-26 | — | — | US | disclosed |
| US-11318130-B2 | 2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2022-05-03 | — | — | US | disclosed |
| US-11219628-B2 | Replacement of cytotoxic preconditioning before cellular immunotherapy | AVM BIOTECHNOLOGY, LLC (US) | 2022-01-11 | — | — | US | disclosed |
| US-10918635-B2 | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200276182-A1 | 2 x 2 x 2 WEEK DOSING REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 3.75% IMIQUIMOD | BAUSCH HEALTH US, LLC | 2020-09-03 | — | — | US | disclosed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019192239-A1 | USE OF TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL TRPV3 IN DEVELOPING DRUG FOR PREVENTION OR TREATMENT OF PSORIASIS | 中国药科大学 | 2019-10-10 | — | — | WO | disclosed |
| US-20190216796-A1 | LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS | SALIX PHARMACEUTICALS, LTD. | 2019-07-18 | — | — | US | disclosed |
| US-20050266024-A1 | Adjuvant | POWDERMED LIMITED | 2005-12-01 | — | — | US | disclosed |
| US-20050256070-A1 | Adjuvant | BRAUN RALPH P | 2005-11-17 | — | — | US | disclosed |
| WO-2005102296-A2 | COMBINATIONS FOR THE TREATMENT OF IMMUNOPROLIFERATIVE SKIN DISORDERS SUCH AS PSORIASIS | HEPTAGEN LIMITED (GB) | 2005-11-03 | — | — | WO | disclosed |
| EP-1487486-A2 | IMIDAZOQUINOLINEAMINES AS ADJUVANTS IN HIV DNA VACCINATION | Powdermed Limited (GB) | 2004-12-22 | — | — | EP | disclosed |
| EP-1487485-A2 | IMIDAZOQUINOLINE ADJUVANTS FOR VACCINES | Powdermed Limited (GB) | 2004-12-22 | — | — | EP | disclosed |
| WO-2004093831-A2 | CYTOKINE-EXPRESSING CELLULAR VACCINE COMBINATIONS | CELL GENESYS, INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20030190308-A1 | Adjuvant | BRAUN RALPH P (US) | 2003-10-09 | — | — | US | disclosed |
| US-20030185835-A1 | Adjuvant for vaccines | POWDERJECT RESEARCH LIMITED (GB) | 2003-10-02 | — | — | US | disclosed |
| WO-2003080114-A2 | IMIDAZOQUINOLINE ADJUVANTS FOR VACCINES | POWDERMED LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
| WO-2003080112-A2 | IMIDAZOQUINOLINEAMINES AS ADJUVANTS IN HIV DNA VACCINATION | POWDERMED LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200276182-A1 | 2 x 2 x 2 WEEK DOSING REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 3.75% IMIQUIMOD | ADRA2A, ALDOA, TOP2A | TLR7 114/4885PDE4D 286/4885ADORA2A 45/4885 |
| US-11850245-B2 | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts | TLR3, IFNAR1, AADAT | TLR7 5/4885PDE4D 127/4885ADORA2A 112/4885 |
| US-11318130-B2 | 2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod | ADRA2A, ALDOA, TOP2A | TLR7 213/4885PDE4D 204/4885ADORA2A 37/4885 |
| US-20050266024-A1 | Adjuvant | TLR9, POLN, TLR3 | TLR7 20/4885PDE4D 1900/4885ADORA2A 1545/4885 |
| US-20230020422-A1 | LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS | TLR3, IFNAR1, AADAT | TLR7 5/4885PDE4D 127/4885ADORA2A 112/4885 |
| US-20030190308-A1 | Adjuvant | TLR9, TLR3, TLR5 | TLR7 9/4885PDE4D 1109/4885ADORA2A 817/4885 |
| US-20190216796-A1 | LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS | TLR3, IFNAR1, AADAT | TLR7 5/4885PDE4D 127/4885ADORA2A 112/4885 |
| US-20030185835-A1 | Adjuvant for vaccines | TLR9, TLR3, TLR5 | TLR7 5/4885PDE4D 1752/4885ADORA2A 635/4885 |
| US-20050256070-A1 | Adjuvant | TLR9, TLR3, TLR5 | TLR7 9/4885PDE4D 1109/4885ADORA2A 817/4885 |
| US-10918635-B2 | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts | TLR3, IFNAR1, AADAT | TLR7 5/4885PDE4D 127/4885ADORA2A 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.